A Study of MHB118C Injection in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. History of ≥2 primary malignancies within 5 years prior to informed consent.
• •2. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks (2 weeks for palliative bone radiotherapy), or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.
• •3. Brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
• •4. Severe lung disease affecting pulmonary function.
• •5. Active systemic infection requiring treatment within 7 days before dosing.
• •6. Serious cardiovascular or cerebrovascular diseases
• •7. Uncontrolled third-space effusions not suitable for enrollment.
• •8. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
• •9. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
• •10. Known alcohol or drug dependence.
• •11. Pregnant or breastfeeding women, or individuals planning to conceive.